Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

0.7903 +0.0676 (+9.35%)
Streaming Delayed Price Updated: 11:30 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
From Rallybio Corporation
Via Business Wire
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
News headline image
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
From Rallybio Corporation
Via Business Wire
News headline image
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.